GlassScriptPhysician profile
Vikramjeet Saini
NPI 1346569704
$20,876.75
in general payments reported to CMS, 2019-2025
26 companies · $2,601 in 2025
The $2,601 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,836 · 2020: $2,222 · 2021: $2,507 · 2022: $2,012 · 2023: $6,750 · 2024: $1,949 · 2025: $2,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,691 · Consulting Fee: $3,743 · Travel and Lodging: $2,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,691.42 |
| Consulting Fee | $3,742.50 |
| Travel and Lodging | $2,865.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $11,925.00 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Spinal Simplicity, LLC | $5,747.16 | 2023-2024 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $588.76 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Nalu Medical, INC. | $579.13 | 2021-2025 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $474.08 | 2023-2025 | Evoke, Evoke Scs |
| Vertos Medical, INC. | $397.93 | 2020-2024 | Mild Device Kit |
| Vertiflex, INC. | $163.71 | 2019 | |
| Stryker Corporation | $144.59 | 2024 | Mild Device Kit |
| Medtronic USA, INC. | $128.93 | 2019-2020 | |
| Nuvasive, INC. | $108.09 | 2021 | |
| Medtronic, INC. | $99.08 | 2023-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Surgalign Spine Technologies, INC. | $70.34 | 2020 | |
| Valinor Pharma, LLC | $66.68 | 2024 | Movantik |
| Protega Pharmaceutials INC | $63.86 | 2024-2025 | Roxybond |
| Pacira Therapeutics, INC. | $56.28 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $42.07 | 2020-2021 | |
| Genzyme Corporation | $35.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.90 | 2020-2022 | |
| Abbvie INC. | $26.78 | 2024 | |
| Amgen INC. | $24.59 | 2019 | |
| Ucb, INC. | $19.18 | 2019 | |
| Averitas Pharma INC. | $19.09 | 2025 | Qutenza |
| Fidia Pharma USA INC. | $18.97 | 2021 | |
| Allergan, INC. | $15.37 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.97 | 2021 | |
| Nevro Corp. | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikramjeet Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.